HMOX1 inhibitors enhance the anti-tumor effects of anti-PD-L1 antibodies in mouse melanoma and also reduce tumor size by abolishing resistance to anti-PD1 immunotherapy in female mice bearing E0771 mammary tumors (43). Here, HMOX1 is linked to melanoma.